Status:
COMPLETED
Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects
Lead Sponsor:
Neuromed IRCCS
Conditions:
Hypertension
Eligibility:
All Genders
30-70 years
Brief Summary
Aim of this study is to enhance the knowledge of myogenic tone alterations in hypertensive patients and to better understand the mechanisms controlling the myogenic tone. Evaluations will be performed...
Eligibility Criteria
Inclusion
- Males or females between 30 and 70 years of age
- Hypertensive patients: Patients with a previous diagnosis of hypertension
- Normotensive patients: subjects without story of hypertension
- Written informed consent
Exclusion
- Severe hypertension (eg, systolic \>180 mm Hg, diastolic \>110 mm Hg)
- Manifested or suspected secondary hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, pheochromocytoma)
- History of cardiac complications (previous acute myocardial infarction (AMI), unstabile angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), congestive heart failure (NYHA II-IV))
- Diabetes mellitus
- Renal pathologies (creatinine clearance \< 30 ml/min)
- Severe hepatic dysfunction
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT02312193
Start Date
January 1 2015
End Date
December 1 2020
Last Update
January 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Neuromed
Pozzilli, Isernia, Italy, 86077